Table 4.
Prescribed anti-inflammatory sarcoidosis therapies
| Total Number | Positive 60 | Negative 208 | ||||
| Current | Past | Never | Current | Past | Never | |
| Prednisone | 37 (61.7%)* | 20 | 3 | 120 (57.7%) | 62 | 26 |
| Methotrexate | 22 (36.7%) | 18 | 20 | 89 (42.8%) | 45 | 74 |
| Azathioprine | 6 (10.0%) | 4 | 50 | 21 (10.1%) | 16 | 171 |
| Leflunomide | 7 (11.7%) | 5 | 23 | 17 (8.2%) | 9 | 182 |
| Mycophenolate | 3 (5.0%) | 0 | 57 | 4 (1.9%) | 1 | 203 |
| Hydroxychloroquine | 6 (10.0%) | 7 | 47 | 32 (15.4%) | 18 | 158 |
| anti-TNF † | 13 (21.7%) | 6 | 41 | 34 (16.3%) | 23 | 151 |
| Rituximab | 2 (3.3%) | 1 | 57 | 6 (2.9%) | 2 | 200 |
| Repository corticotropin injection | 3 (5.0%) | 0 | 57 | 13 (6.3%) | 2 | 193 |
*Percent on current therapy per group
anti-TNF: anti-tumor necrosis factor monoclonal antibody either infliximab or adalimumab